Table 1.
Author (Year) | n | Subjects | Gender | Intervention | IMCL | % Change | Muscle Investigated | Comments |
---|---|---|---|---|---|---|---|---|
Christ (2016) [67] | 10 | Volunteers with adult-onset GHD | m, f | 2 h exercise at 50%–60% VO2 max on a treadmill | ↓ * | −9.3 to −13.5 | M. tibialis anterior | No significant effect of growth hormone replacement therapy on IMCL and IHCL, IHCL ↑ * |
Bucher (2014) [43] | 10 | Healthy volunteers | m | 2 h exercise on bicycle ergometer at 50%–60% VO2 max | ↓ * | −16.8 | M. vastus intermedius | IHCL ↑ *, ICCL ↓ * |
Egger (2013) [44] | 18 | Healthy volunteers | m, f | 2 h exercise on treadmill at 50%–60% VO2 max | ↓ * | −22.6 | M. tibialis anterior | IHCL ↑ * |
Vermathen (2012) [47] | 8 | Trained cyclists or runners | m | 3 h exercise on bicycle ergometer or treadmill at 50% Wmax | ↓ * | −3 to −50 | Thigh (M. vastus intermedius, vastus lateralis, vastus lateralis, adductor magnus, biceps femoris; rectus femoris) or lower leg muscle (tibialis anterior, soleus lateralis, soleus medialis, gastrocnemius lateralis, gastrocnemius medialis, extensor digitorum) | In M. biceps femoris and rectus femoris no significant decrease |
Jenni (2008) [65] | 7 | Physically active men with T1DM | m | 2 h cycling at 55%–60% VO2 max | ↓ * | −11.5 to −16.2 | M. vastus intermedius | |
Trepp (2008) [66] | 15 | Volunteers with adult-onset GHD | m, f | 1 h walking at heart rate corresponding to 50% VO2 max, on three days and low fat diet | ↓ * | −35 to −47.5 ** | M. tibialis anterior | No significant effect of growth hormone replacement therapy on IMCL |
De Bock (2007) [48] | 9 | Physically active men | m | 2 h cycling at 75% VO2 peak | ↓ * | −47 | M. vastus lateralis | |
Zehnder (2006) [37] | 11 | Endurance trained cyclists | m | 3 h cycling at 50% Wmax | ↓ * | −21 to −41 | M. vastus intermedius | |
Zehnder (2005) [49] | 18 | Cyclists or triathletes | m, f | 3 h cycling at 50% Wmax | ↓ * | −42 to −59 | M. vastus intermedius | Larger reduction in males |
Schrauwen-Hinderling (2003) [50] | 8 | Highly trained cyclists | m | 3 h cycling at 55% Wmax | ↓ * | −20.4 | M. vastus lateralis | M. biceps brachii ↑ * |
Van Loon (2003) [51] | 9 | Endurance-trained cyclists | m | 3 h cycling at 55% Wmax | ↓ * | −21 | M. vastus lateralis | No difference between normal and low-fat diet |
White (2003) [46] | 9 | Moderately active | m | 45 min cycling, intervals at 50% and 110% of ventilator threshold | ↓ * | −38 | M. vastus lateralis | |
White (2003) [45] | 18 | Moderately active | m, f | 1 h cycling at 65% VO2 max | ↓ * | −11.5 to −17.1 | M. vastus lateralis | |
Johnson (2003) [52] | 6 | Highly trained cyclists | m | 3 h cycling at 70% VO2 max | ↓ * | −57 to −64 | M. vastus lateralis | Higher IMCL degradation in low carbohydrate condition |
Larson-Meyer (2002) [38] | 7 | Well-trained endurance runners | f | 2 h running at 65% VO2 max | ↓ * | −25 | M. soleus | |
Brechtel (2001) [53] | 12 | Well-trained subjects | m | Running: parallel design 60%–70% VO2 max, 80%–90% VO2 max 21/42 km | ↓ | −10 to −42 | M. tibialis anterior, M. soleus | |
Krssak (2000) [54] | 9 | Trained subjects | m, f | 3–4 bouts of 45 min of running at 65%–70% peak oxygen until exhaustion | ↓ * | −33.5 ** | M. soleus | |
Rico-Sanz (2000) [55] | 5 | Trained subjects | m | 90 min running at 64% VO2 max | ↓ * | −15.7 to −32.2 ** | M. soleus, tibialis, gastrocnemius | in M. gastrocnemius no sign decrease |
Rico-Sanz (1998) [68] | 8 | Trained subjects | m | 13.2 km running, jogging, sprinting | → | +9 to −2.4 ** | M. soleus, gastrocnemius, tibialis |
n: number of subjects; IMCL: intramyocellular lipids comparison pre- and post-exercise; *: significant (p < 0.05); IHCL: intrahepatocellular lipids; ICCL: intracardiomyocellular lipids; MRS: 1H-MR-Spectroscopy; T1DM: Type 1 diabetes mellitus; m: male; f: female; GHD: growth hormone deficiency; % change: relative change from baseline (in percentage); **: original values converted to relative change; ↓: decrease; ↑: increase; →: no change.